AbbVie_IU_icons_outlined_v3AbbVie_IU_icons_outlined_v3checkmarkcheckmark24C1F2D2-A1A6-4D15-982D-20E53E43CC8BAbbVie_IU_icons_outlined_v3AbbVie_IU_icons_outlined_v3AbbVie_IU_icons_outlined_v3
hcv-global-hero@2x

Hepatitis C

A Global Health Problem.

Despite advances in care, the hepatitis C virus (HCV) remains a global health problem, requiring continued collaborative action to elevate awareness, increase diagnosis and improve linkage to care for all people living with the disease.

Read About Our Latest Efforts in HCV

AbbVie Announces Approval of MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in Japan
Read More

European Commission Grants AbbVie’s MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
Read More

AbbVie Receives CHMP Positive Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
Read More

 

About Hepatitis C

Hepatitis C is an infectious liver disease resulting from infection with HCV.1

It typically spreads when blood from an infected person enters the body of someone who is not infected.1

71 million people are infected with HCV worldwide.2 The reported incidence of new infections is estimated at nearly 24 cases per 100,000 people annually. Since the disease often has no symptoms, the actual incidence may be much higher.2

The millions of people living with HCV have varied needs, depending on their specific genotype, fibrosis stage and other characteristics.

Why Many People Remain Untreated

Today’s treatments can cure the majority of HCV patients.3 However, many people remain undiagnosed or not even treated due to multiple barriers along the patient journey.4,5,6

There are ways to reduce the risk of HCV-related health conditions and death, as well as lower long-term healthcare costs.7,8 This includes improving screening and diagnosis, increasing referrals to specialists and expanding access to treatment.

 

Screening & Diagnosis

Without systematic screening processes, patients may be undiagnosed for decades due to HCV’s asymptomatic nature and low awareness of disease severity.9

Referral to Specialist

General practitioners (GP) are critical to identifying, diagnosing, and referring patients to specialists.6 Lack of awareness among general practitioners may impede early diagnosis and timely referral to a specialist.12

Receiving Care

Even when they are under the HCV treater’s care, a significant number of patients are not being treated (or treatment being delayed)12

The Burden of HCV

Hepatitis C leads to serious health consequences, which can ultimately result in death. The human, social and economic costs of HCV are high and increase as the disease progresses.

calendar icon

Over time, HCV can cause liver cirrhosis and liver cancer.1,9,15 Approximately 399,000 people die each year from hepatitis C-related liver disease.2

heart in hand icon

HCV carries significant stigma, which can impact a person’s quality of life including self-esteem, relationships, productivity and mental health.16

government building icon

HCV places an enormous economic toll on society due to lower quality of life in patients and increasing healthcare costs in later stages of the disease.17,18,19

Our Commitment to HCV

play button

Together with the HCV community, we are working to helping end HCV through awareness, screening, diagnosis and linkage to care programs.

Read Other Stories

How a World Free from Viral Hepatitis is Possible
Read More

Exploring the “Why” Hepatitis C with Betty Yao, Ph.D.
Read More

Join The Conversation!

Follow our social channels for our latest HCV news and insights.

References

1. Hepatitis C: General Information. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/hepatitis/hcv/pdfs/hepcgeneralfactsheet.pdf.

2. World Health Organization. Global hepatitis report 2017. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1.

3. Decisions Resources Group. Hepatitis C virus: disease landscape & forecast 2016. January 2017.

4. POLARIS Observatory (2017).

5. Mcgowan, CE and Fried, MW. "Barriers to Hepatitis C Treatment." Liver International 32 (2012): 151-56. Web. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955982/.

6. The Boston Consulting Group. Road to Elimination: Barriers and Best Practices in Hepatitis C Management. July 2017.

7. Nuno Solinis, Roberto, Patricia Arratibel Ugarte, Ander Rojo, and Yuri Sanchez Gonzalez. "Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence." Infectious Diseases and Therapy 5.4 (2016): 491-508. SpringerLink. 25 Oct. 2016. http://link.springer.com/article/10.1007%2Fs40121-016-0134-x.

8. Papatheodoridis, GV, et al. Hepatitis C: The beginning of the end—key elements for successful European and national

9. World Health Organization. Hepatitis C Fact Sheet. 2017. http://www.who.int/mediacentre/factsheets/fs164/en/.

10. Manns MP, et al. Hepatitis C virus infection. Nat Rev Dis Primers. 2017; 3:17006.

11. Pratt, A, et al. EASL 2017, Amsterdam. #PS-189.

12. Miani C et al. Hepatitis C: Understanding factors that influence the physicians’ treatment decisions (2016) Accessed at: https://www.rand.org/pubs/research_reports/RR263.html.

13. Grebely, J, et al. The Journal of infectious diseases 207 (Suppl 1), 2013. S19–S25.

14. World Health Organization. Progress Report on Access to Hepatitis C Treatment. March 2018.

15. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol (2016). http://dx.doi.org/10.1016/j.jhep.2016.09.001.

16. Miller ER, McNally S Wallace J Schlichthorst M. The ongoing impacts of hepatitis c - a systematic narrative review of the literature. BMC Public Health. 2012; 12:672.

17. Su J et al. The Impact of Hepatitis C Virus Infection on Work Absence, Productivity, and Healthcare Benefit Costs. Hepatology 2010;52(2):436–442.

18. El Khoury AC, Vietri J, Prajapati G. The burden of untreated hepatitis C virus infection: a US patients' perspective. Dig Dis Sci. 2012; 57(11):2995-3003.

19. McAdam-Marx C et al. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011;17:531-46.

This site uses cookies to personalize content, save your preferences and track the site’s performance. Learn more, including how to disable certain cookies on our Privacy Page. Click OK to continue.